Context.-Implementation of proficiency testing for gynecologic cytology was delayed 20 years because of challenges addressing the subjective nature of cytologic interpretation and replicating normal working conditions. Concern remains regarding test scoring, slide validation, test environment, and other issues. How these test results are, or should be, used in quality management has never been explored.
Context.-Implementation of proficiency testing for gynecologic cytology was delayed 20 years because of challenges addressing the subjective nature of cytologic interpretation and replicating normal working conditions. Concern remains regarding test scoring, slide validation, test environment, and other issues. How these test results are, or should be, used in quality management has never been explored.
Objective.-To provide information on good laboratory practices for gynecologic cytology proficiency testing based on findings from the College of American Pathologists' survey-based project funded by the Centers for Disease Control and Prevention.
Data Sources.-An expert working group evaluated results from a Web-based, national laboratory survey plus responses from follow-up questions and findings from the literature. The group created statements on good laboratory practices pertinent to proficiency testing and its role in quality management, which were discussed and voted on at a consensus conference.
Conclusions.-Two-thirds of laboratories report having an individual with an unsuccessful proficiency testing score. More than 90% did not initiate any remedial action for 1 or 2 unsuccessful tests; 84% of laboratories reported they actively monitored results from proficiency testing, but most laboratories did not initiate any remedial action for cytotechnologists (81.4%; 376 of 462) or pathologists (87.7%; 405 of 462) who passed a proficiency test but who did not score 100%. Proficiency testing pass-fail rates should be monitored globally for the laboratory and for each individual. Proficiency testing slides should be prescreened by cytotechnologists for pathologists who are not primary screeners. Remedial action should not be required for a passed, but imperfect, test. No remedial action is required for an unsuccessful, first proficiency test result before retesting.
(Arch Pathol Lab Med. 2013;137:183-189; doi: 10.5858/ arpa.2012-0094-OA) P roficiency testing (PT) in cytopathology was introduced nationally in 1988 as part of the Clinical Laboratory Improvement Amendments (CLIA '88) to ensure ''. . . periodic confirmation and evaluation of the proficiency of individuals involved in screening or interpreting cytological preparations....'' 1(p6 of 42USC §263a) Federal regulation requires that each individual involved with screening and interpreting gynecologic cytology (Papanicolaou [Pap] test) preparations take an annual test and pass with a score of 90%. However, implementation of this regulation did not occur until almost 20 years after the law because there were many challenges in creating a test that adequately addressed the subjective nature of cytologic interpretation and that replicated normal working conditions, as the regulation required. Proficiency testing was implemented in 2005 and consists of 10 slides that must be completed within 2 hours. The federal regulation allows an individual as many as 4 opportunities to pass the test. A variety of publications followed implementation, which expressed concern about test scoring, slide validation, and test environment. 2-13 Some of those concerns were addressed in subsequent versions of the test, but despite perceived imperfections and on-going controversies, practitioners have generally shown excellent test performance scores. Results from the 2006 College of American Pathologists (CAP) PAP PT program for cytopathology shows that 99.6% of test takers pass in 3 attempts or less, and that the rate of an initial unsuccessful test has declined over time to 2% to 7%. This experience parallels that of proficiency testing in other areas of the clinical laboratory, such as chemistry and hematology. 14 (Table 1) .
The role of PT in a cytopathology laboratory's quality program is, however, quite separate from compliance with the federal mandate to be tested. How these test results are used, or should be used, by laboratory supervisors and directors has never, to our knowledge, been explored and has not been addressed in any previous CAP surveys. This national survey of quality practices in gynecologic cytopathology, conducted by CAP and funded by a contract from the Centers for Disease Control and Prevention (CDC), provides a unique opportunity to address this information gap and to gain a national perspective on current laboratory practices and opinions in this area. The purpose of this report is to review the findings from that survey pertinent to PT and to provide statements regarding good laboratory practices based on the survey data, published studies, and expert opinion.
METHODS
The CAP, with support by a cooperative agreement from the CDC, conducted a national survey of quality assurance practices in gynecologic cytology. The details of the complete process of this study, including survey development, enhanced input from Webbased questions, and culmination in a consensus conference, are fully described in another report. 16 Briefly, the survey was developed by the 3 pathologists who led this project and consisted of 99 questions in 9 broad categories, 1 of which was devoted to proficiency testing. The survey was first piloted in 10 laboratories and later submitted to 1245 laboratories identified from a CDC list of CLIA-registered cytopathology laboratories in addition to those enrolled in the CAP gynecologic PT program (CAP-PAP) and those who responded to an informational advertisement. Survey responses were anonymous and, of the 596 laboratory respondents, data was used from 541 laboratories (91%; 43% response rate) because of incomplete survey responses from the remainder.
Expert cytopathologists and cytotechnologists (CTs) were recruited and assigned to 5 working groups that studied the survey data from assigned survey categories. These working groups added follow-up questions to the survey, which were available in a Webbased site, to elicit additional opinions. Evaluating the data and follow-up questions, together with a review of the literature, the working groups developed a series of preliminary statements on good laboratory practices in cytology quality assurance and presented them at a consensus conference in Rosemont, Illinois, on June 4, 2011. Participants in the conference included working group members, representatives from national cytopathology and cytotechnology organizations, the federal government, and individuals who accepted invitations after completing the online survey. Representatives from each working group presented background information, results from detailed literature reviews, and their preliminary draft statements at the conference. The survey results were then discussed with the objective of achieving agreement on controversial issues. Following that, a ballot was taken on a series of questions, which was designed to address these controversial issues. Results of the ballot were stratified by level of agreement as follows: 99%þ was considered nearly complete agreement, 90% to 98% indicated strong agreement, 80% to 89% indicated moderately strong agreement, and 70% to 79% indicated agreement. Less than 70% was not considered sufficient for agreement. These levels of agreement were chosen following discussion and consensus by all working-group chairs and project leaders.
RESULTS

Survey
Table 2 describes laboratories' experiences with proficiency testing during the 4 years before the survey. Almost twothirds of laboratories report having an individual with an unsuccessful PT event during this period. The incidence of an unsuccessful PT event during the 4 year period was reported to be 59.2% (151 of 255) for CTs and 64.3% (164 of 255) for pathologists. One-third (84 of 255; 32.9%) of the laboratories report having at least one CT with an unsuccessful PT result because she or he answered ''negative for squamous intraepithelial lesion'' for a high-grade squamous intraepithelial lesion (HSIL). Only 18% of laboratories (46 of 255) reported that this happened for pathologists. Although unsuccessful first-time takers of PT were fairly frequent during this period (2005-2009), federal regulation allows 3 additional test attempts, and lack of success in subsequent tests was very uncommon (2.7% in each group; 7 of 255 each). More than 90% of laboratories (383 of 461; 398 of 461) did not initiate any remedial action for 1 or 2 unsuccessful tests, other than those required by CLIA. Table 3 illustrates PT laboratory practices. More than 95% of laboratories report that they actively monitor results from PT, including monitors for individual cytotechnologists and pathologists; however, only half do so globally for the entire laboratory. Pass-fail rate is monitored by almost all laboratories (444 of 471; 94.7%), and no other PT monitor was reported to be a common practice, including monitoring diagnoses of ''missed'' test slides, which was only reported as a practice by one-quarter of laboratories (124 of 470; 26.4). Almost all laboratories (93.9%; 476 of 507) have PT slides pre-screened by a cytotechnologist for testing pathologists.
Enrollment for retesting is the most common response to an unsuccessful test for both CTs (83.1%; 383 of 461) and pathologists (86.3; 398 of 461), although only 61.7% (284 of 460) of laboratories report having this practice documented in a policy (Table 4 ). Initiating remedial action following an unsuccessful test was uncommon among the responding laboratories. Focused, in-house education was the action most frequently reported, although this response was provided by only 12.6% of laboratories (58 of 461) for CTs and 8.2% of them for pathologists (38 of 461). Dismissal was 2005  7  33  10  2006  5  17  5  2007  3  11  3  2008  3  11  3  2009  3 rare for either CTs (1.5%; 7 of 461) or pathologists (0.9%; 4 of 461). Table 5 shows that most laboratories do not initiate any remedial action for CTs (81.4%; 376 of 462) or pathologists (87.7%; 406 of 462) who pass a proficiency test but do not score 100%. Among the few that do initiate action, 2 consecutive unsuccessful tests was the most commonly reported circumstance that would prompt remediation (5.2%; 24 of 462 each). Three percent of laboratories (3.2%, or 15 of 462 for MDs; 3.7%, or 17 of 462 for CTs) reported that circumstances other than consecutive test failure would prompt remediation (Table 6) .
Web-Based Follow-Up Questions
Thirteen additional follow-up questions were posted on a Web-based site linked from the CAP Web site. These questions were created by the working group after review and analysis of the survey responses and were intended to further explore the survey findings. As many as 48 responses were received to these follow-up questions, although not all respondents posted answers to each question. Unlike the initial survey, which permitted only one set of responses per laboratory, it was possible for more than one individual from a laboratory to respond to the posted questions.
Seventy-nine percent of respondents (38 of 48) said that PT was incorporated into their laboratory's quality plan. When asked why PT was included, almost half (11 of 28) indicated that PT was included because of federal or local requirements. Of the remainder, 5 (18%) of the 28 comments specifically described PT as having limited or uncertain significance. There was little enthusiasm for using PT as a measure of competency and performance (4 of 28; 14%). Representative comments reflecting these findings include ''We include it because it's a federally mandated test and requisite for practice. We weight it relatively lowly because 10 slides are a poor performance indicator compared with a year's worth of quality assurance data''; ''We have to take the test so you might as well add it into the plan''; ''Unsure that PT results are meaningful'' and ''Useless info.''
Opinion was almost equally divided as to whether there were other methods or measures that could replace the currently administered PT and provide the external measure of individual proficiency or performance that is required by the current federal regulation (yes, 38%; no, 27%; unsure, 36%). Common themes for improvement among the submitted, written comments included extending the test interval, using computerized images for testing, and replacing PT with quality parameters currently used in laboratories, such as the ratio for results of atypical squamous cells versus results of squamous intraepithelial lesion, Pap to biopsy correlations, comparisons of individual performance to laboratory-wide abnormal and unsatisfactory rates, and findings from the required 5-year rescreening for new HSIL diagnoses.
Despite the CLIA requirement that PT mimic normal practice, only 45% of respondents felt that steps taken to administer PT were the same as those used to screen and interpret slides in their regular practice, and 5% were unsure that this was the case. More than three-quarters of the written comments expressed concern that PT did not allow consultation with colleagues or textbooks, both of which are common in daily practice when evaluating difficult cases. Other deviations from standard practices that were raised as issues in the comments included absence of full Bethesda terminology as a test response, particularly atypical squamous cells of undetermined significance; the time constraints for completion of the test, and the presence of slide artifacts. Representative comments reflecting these findings included ''We seek additional opinions on cases we have difficulty with, which is not an option with PT. We also check electronic medical record data and often call clinicians for additional info on problematic cases, also not an option with PT''; ''There are less distractions and interruptions during PT as well as there are artificial categories (HSILþ, no atypical squamous cells of undetermined significance, atypical glandular cells, etc.)''; and ''We do a lot of case sharing and group consensus on difficult cases in our real workload. I don't think PT mimics real practice at all.'' Most (76%) of the Web-based respondents report they do not use PT results to determine workload. Most (72%) also do not consider an unsuccessful first-time PT to be a significant finding warranting remedial action, although a few responded that they were unsure (20%). Representative comments included ''People are nervous. It's a fake life situation''; ''Sometimes the slides are terrible and do not look [like] our daily slides, and some people do not do well when taking tests due to nervousness etc., regardless of what the test is''; ''Depends on what the failure is for. If cancer was missed than yes; If low-grade squamous intraepithelial lesion (LSIL) and it was a faded slide, no''; and ''Actually it depends on the individual cytotech[nolotist]. Are they experienced or new? Are they good test takers or do they freak out at the word 'test'?'' Even more of the Web-based respondents (89%) did not consider a passed-but-imperfect score (ie, less than 100%) to require remediation, with far fewer unsure respondents (9%). Comments once again strongly emphasized the effect of test anxiety, the subjective nature of cytologic interpretation, and the inability to mimic real-life practice, particularly the inability to consult with colleagues. Repre-sentative comments included ''The cases are not always that straightforward, and again, in a real scenario you might send in a case to a pathologist that you questioned atypia that was eventually called negative''; ''Generally the miss is not an identifying issue, but [a] degree or level of disease (LSIL versus HSIL). Slide quality and stain different from home lab may also be a cause for degree miss''; and ''Subjectivity is our profession. 100% is simply unreasonable in [a] field with so much intraobserver variability.''
GOOD LABORATORY PRACTICES: CONSENSUS STATEMENTS AND COMMENTS
The following consensus statements were created based on the above survey findings, input from discussion board, review of pertinent literature, expert opinion, and conference discussion. The vote from the consensus conference participants is included below to demonstrate level of support for each statement.
1. The laboratory should have a written policy that the director (and/or designee) actively monitors results of gynecologic cytology proficiency testing. Comments: Most laboratories (84.2%; 448 of 532) report in the survey that they have a policy as described above. CLIA '88 requires directors to actively monitor PT results. The working group and conference participants believe that there should be a written policy that formally acknowledges the laboratory's awareness of the CLIA '88 requirement and its commitment to comply.
Consensus vote: 86.4%, yes (strong agreement); 12.1%, no; 1.5%, other. 2. Pap PT pass-fail rates should be monitored globally for the laboratory and by individual practitioner (ie, CT and pathologist). Comments: Monitoring PT pass-fail rates is required by CLIA '88. Survey data reveal that almost all laboratories (94.7%; 444 of 469) monitor pass-fail rates in some form; Comments: 93.9% (476 of 507) of laboratories report that Pap PT slides are prescreened by CTs for pathologists who are not primary screeners. The working group and conference participants agree that this practice most closely reflects the normal practice environment, as required by CLIA '88. However, the Web-based comments and comments at the consensus conference expressed concern that other practices considered important to the normal practice environment are not allowed in a PT, such as consultation with colleagues, and that remained an area of significant concern.
Consensus vote: 89.1%, yes (moderately strong agreement); 10.1, no. Comments: CLIA '88 allows an individual as many as 4 opportunities to pass the PT. The survey reveals that enrollment and retesting is the only action taken by most laboratories and is required by 83.1% (383 of 461) of the laboratories for CTs and 86.3% (398 of 461) of the laboratories for pathologists. None of the other options provided in the survey were commonly employed, including in-house education on diagnostic criteria; increasing the percentage of random, quality-control. rescreened cases for the individual who failed; counseling and monitoring; decreased workload; removal from screening; auditing of previous cases; and additional, external continuing education. This minimal response to unsuccessful PT appears to reflect the opinion of laboratories that a one-time failure is not a significant finding, which was also demonstrated in the Web-based follow-up questions. As one respondent said, ''Oh come on-everyone has a bad day.'' None of the respondents indicated that they had been aware of any previous performance problems with those who had failed PT.
Test anxiety was the most common reason for failure provided by the respondents in the follow-up questions, and published reports have demonstrated that anxiety does alter test performance. 12, 13 Familiarity with the test over time most likely explains the decline in the rate of unsuccessful initial tests during the first 5 years that the test was offered and that 99.6% of test-takers will pass after 3 tests. 14, 15 Lingering concern regarding the validity of PT may also contribute to the absence of required remediation when an individual fails PT because Webbased comments emphasized variable slide quality, issues with test scoring, and inability to consult colleagues. Notably only 61.7% (284 of 461) of laboratories reported that they had a written policy specifying enrollment and re-testing for an unsuccessful PT test. As indicated above, the working group and conference participants believed that a written policy formally acknowledges the laboratory's awareness of the CLIA '88 requirement and its commitment to comply.
Consensus vote: 94.4%, yes (strong agreement); 5.6%, no. 5. Remedial action should not be required for a passed-butimperfect test result (ie, score of ,100%), even for multiple, nonperfect test scores. Comments: 81.4% (376 of 462) of laboratories reported that they do not monitor passed-but-imperfect test results, and comments provided in the follow-up questions indicated that this was due to the subjective nature of the test. Even if 2 consecutive tests are passed with less-than-perfect scores, only 5.2% of (24 of 461) of the laboratories reported that they would take any sort of remedial action, and 0.2% (1 of 462) of the laboratories report that they would do so for 3 imperfect tests. There is no published literature or other evidence to indicate that a passed but less-than-perfect score is an indicator of less-than-optimal quality or performance by CTs or pathologists.
Consensus vote: 93.8%, yes (strong agreement); 6.2%, no. 6. Monitoring of incorrect slide diagnoses on passed PT tests:
a. Is discouraged from inclusion in laboratory PT policy. b. No intervention for this test finding is necessary.
Comments: 74% of laboratories (346 of 470) reported that they do not monitor incorrect slide diagnoses on passed PT tests. There is no published literature or other evidence to indicate that a passed but less-than-perfect score is an indicator of less-than-optimal quality or performance by CTs or pathologists.
Consensus vote: 76.6%, yes (agreement); 23.4%, no. Conduct an audit of previous cases from individual 7. For laboratories performing more than one slide methodology, each methodology should be tested during PT. Comments: There is no published evidence to indicate that an individual's performance with one test methodology predicts performance with another methodology.
Consensus vote: Strongly agree, 79.6% (agreement); agree, 15.2%; disagree, 3.4%; strongly disagree, 0; unsure, 1.7%. 8. There is room for improvement in using PT testing methods as a monitor, especially in light of new screening technologies. Comments: CLIA '88 requires that the PT closely reflects the normal practice environment. The absence of consideration of new technologies, such as computerassisted screening, in the PT program does not reflect the normal practice environment for those laboratories that regularly use these technologies and, therefore, cannot adequately address an individual's performance or proficiency.
Consensus vote: 73.7%, yes (agreement); 22.8 %, no; 3.5%, unsure.
COMMENT Proficiency testing is included as a requirement in CLIA '88 to meet the public's expectation that laboratories are sufficiently skillful and competent in the testing that they offer. Many of the findings in this survey demonstrate that cytology laboratories fulfill the intent of that requirement because most monitor PT pass-fail rates for their personnel and respond to failures with enrollment and retesting, as required. However, most laboratories appear to ''grin and bear it'' because the survey also demonstrates that laboratories do not indicate any meaningful role for PT results in their laboratory quality plan and rarely initiate any remedial action for one or even multiple, unsuccessful test results. This is not particularly surprising because the survey findings and Web-based comments reflect the longstanding skepticism of the cytology community regarding the value of PT as a quality indicator. Since its inception, there have been many concerns regarding cytology PT. Unlike other areas of the clinical laboratory, where test performance can change relatively quickly because of instrument calibration or reagent lot, cytologic testing is based on human interpretation, and there has been no published evidence to suggest human performance deteriorates after 1 year. No professional certifying agency requires annual testing, and in most medical disciplines, a 10-year testing interval has become standard and includes documentation of continuing educational credits between test intervals to ensure maintenance of skills. The many continuous quality improvement monitors routinely performed in cytology laboratories could easily provide a window into individual and laboratory performance in between test intervals. The current, required, annual PT interval is, therefore, felt by many to be excessive and onerous.
The current PT model has also been criticized for not reflecting normal practice, which the CLIA regulation requires, and this survey project demonstrates that this remains a continuing concern among laboratories. The PT does not include established Bethesda System categories for reporting uncertainty, such as atypical squamous cells of undetermined significance, which are frequently used in routine cytologic processing. Acknowledging uncertainty is an important aspect of cytology practice, which is difficult to incorporate into proficiency testing; nonetheless, PT cannot truly reflect normal practice if that is not addressed in some manner. Cytopathology is also a very collaborative practice, which includes regular rescreening of cases and frequent consultation with colleagues on difficult cases; however, the current PT model does not permit consultation and collaboration, nor does current PT allow new technologies, such as computer-assisted and location-guided screening, which have become standard practices in many laboratories. Many of the comments received in response to the Webbased questions addressed the desire to include collaboration and new technologies in PT. By not addressing the practices used commonly in cytology laboratories, PT, as currently designed, does not truly evaluate the test process that it is intended to protect.
There has also long been criticism from the cytology community regarding the scoring system used in the current PT, particularly regarding the 5-point penalty for failure to distinguish LSIL from HSIL. The CAP PT program has shown that interpretative consensus is difficult among the slides used for testing and that, despite field validation, there is a 6% slide failure rate. Most of the appeals in the CAP PT program are HSIL cases interpreted as negative for intraepithelial lesion or malignancy. In reviewing appeals, CAP has found that referees are rarely unanimous and that both participants and referees struggle with reliability and reproducibility of finding rare cells, ''overdiagnosis'' of benign changes, and assigning morphologic, dynamic, biologic changes to static categories, especially when results for uncertainty aren't available as test options. 8 This experience fits with previous studies demonstrating difficulty with interpretative consensus, including findings from the Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study trial, where only 69% of cases had results with consensus by a panel of experts 7 and with published studies from the CAP-PAP program that as many as 19% of cases fail field validation. 2 Interpretative precision that is less with HSIL cases 4 shows that the discrepancy rate between LSIL and HSIL results 3 varies from 9.8% to 15%.
Because of the issues associated with scoring and the professional implications of not passing PT, considerable ''gamesmanship'' has been noted among test takers. The CAP PT slides, those derived from CAP-PAP educational programs, and a comparison of results from slides used in both programs show that more cases that are negative are ''upgraded'' to LSIL/HSIL in PT, and fewer LSILs are classified as negative in PT. This clearly demonstrates a defensive test-taking strategy because of scoring because the most severe penalties are associated with underinterpretation, and overinterpretation, even if extreme, doesn't cause failure. 12 If test takers are not providing results that they would provide in their regular practice, the PT process, once again, does not recreate the normal work environment and is not protecting the test process as intended.
The CLIA '88 regulation allows unsuccessful test takers to retake the PT as many as 3 times before an individual is designated as having failed PT, which reflects awareness and consideration of the inherent pitfalls and imperfections of the testing described above. The PT was never meant to distinguish subtle levels of mastery but was instead intended to evaluate essential and fundamental interpreta-tive competency deemed necessary to practice. As published results from PT indicate, most cytotechnologists and pathologists possess these skills and perform well when tested. 9, 12, 13 Given the current highly qualified workforce, the PT role as a discriminator is thus not currently needed. Detractors, however, claim that the high success rate by those taking PT further demonstrates that PT is a meaningless, but onerous, exercise.
Recognizing the considerable dissatisfaction in the cytology community, the federal government has made efforts to modify PT. In 2006, CMS and the CDC convened a Clinical Laboratory Improvement Advisory Committee PT workgroup whose advice formed the basis for a 2009 proposed rule published by CMS and CDC. More than 6500 comments on the proposed rule were received during the open comment period from about 670 commenters. Other than requesting that PT be eliminated and replaced by continuing education, which was not part of the proposed rule nor within the scope of the CMS authority, there was no consensus in support of the many proposed changes to cytology PT. The CMS, therefore, withdrew the proposed rule and kept the current standards in place because data on test results to date demonstrated that cytology PT is effective in identifying individuals who cannot identify abnormal cells and that most individuals who perform cytology testing do high quality work. 17 Given this history of controversy related to PT, the purpose of this project was to identify the appropriate role of PT in a laboratory's quality plan so that laboratories can support the goal of ensuring the public trust in cytologic interpretation while maintaining the trust of their valuable CTs and cytopathologists who must participate in this federal mandate to provide cytologic services. When creating the Good Laboratory Practices above, the committee's intent was to place PT in the appropriate context, so that laboratories would not highly weight or overinterpret PT as a measure of quality or performance. The Good Laboratory Practices should serve as a guideline for laboratories creating their own policies, so that laboratories comply with federal regulation and use selected PT results to support quality, not in a manner that is punitively to practitioners. Limitations to this project include possible response bias because less than 100% of laboratories responded to the survey, a very small number of comments were submitted on the discussion board, and the survey was only administered electronically. This bias is likely to be minimal because the response rate to the survey was large (43%) and because electronic connectivity and communications are a standard tool in laboratory practice and business relationships, making it unlikely that laboratories would be unreachable electronically.
Remaining areas of controversy or gaps in PT that could benefit from additional research and development in PT include (1) creating meaningful modifications to current PT structure that more closely reflects normal practice and that incorporates new technologies, such as computer-assisted screening; (2) considering how consultation with colleagues could be incorporated into testing and how that addition influences and potentially improves the PT ability to evaluate individual performance; (3) exploring and developing parameters or methods, other than slide tests, which would better evaluate individual performance and serve as a better measure of quality; (4) determining whether monitoring of missed slide diagnoses on passed tests provides a more subtle ''tip of the iceberg'' indication of individual performance gaps; (5) examining whether PT performance with one test methodology can be generalized to other methodologies; (6) and learning how to build trust among cytology practitioners regarding the success and benefit of the current PT process.
